Objective:To explore the genetic characteristics of a child with 18q terminal deletion syndrome.Methods:Clinical data of a child presented at the Lianyungang Maternal and Child Health Care Hospital on July 20, 2023 was collected. Peripheral blood sample from the child was subjected to G-banded chromosomal karyotyping and chromosomal microarray analysis (CMA). Relevant literature was searched from CNKI, WanFang and PubMed databases over the past decade (from November 1, 2013 to November 1, 2023) using keywords including "18q-syndrome", "18q deletion syndrome" and "18q terminal deletion". This study was approved by Medical Ethics Committee of the Lianyungang Maternal and Child Health Care Hospital (Ethics No. LYG-MER2021017).Results:The child, a 4-year-and-6-month-old female, had manifested short stature, intellectual disability, distinctive facial features, aortic regurgitation, auditory canal atresia, and white matter lesions. She was found to have a karyotype of 46, XX, del(18)(q21), whilst the result of CMA was arr[GRCh37]18q21.33q23(60065821_77317445)×1. Both of her parents were found to have a normal karyotype. Literature review has retrieved 7 reports which involved 11 cases with a terminal 18q23 deletion. The phenotypes of cardiac abnormalities have been diverse, with pulmonary stenosis, atrial septal defect and ventricular septal defect being most common.Conclusion:The 18q terminal deletion probably underlay the multiple congenital anomalies and mental retardation in this child.

Objective To prepare paclitaxel-natural borneol complex,and to explore the prescription and preparation process of paclitaxel-natural borneol complex drug-loaded submicroemulsion,and its in vitro anti-tumor effect.Methods The Paclitaxel-natural borneol complex was prepared by grinding method and identified by Fourier Transform infrared spectroscopy(FT-IR)and differential scanning calorimetry(DSC).The compound drug-loaded submicroemulsion was prepared using a two-step high-pressure emulsification method.The single-factor investigation and the orthogonal experimental design were applied to optimize the formulation and preparation process.MTT assay,cell cloning assay,and cell scratch assay were used to evaluate the effect of this preparation on HCT-116 cells.Results The infrared spectral absorption peaks of taxol-natural borneol complex at 3 312.76 cm-1 and 3 513.92 cm-1 disappeared,and DSC analysis showed that a new absorption peak of taxol-natural borneol complex appeared at 154.56 ℃,indicating that taxol be coupled with natural borneol to form a new complex.The optimal prescription was 0.44％active pharmaceutical ingredient[paclitaxel-natural borneol(1∶3)],10％medium chain triglyceride,3％emulsifier[egg yolk lecithin-Poloxam 188(1∶2)],2％glycerol,0.3％oleate.The optimal process was emulsification at 80 ℃,60 MPa high pressure homogenization 10 times.The half inhibitory concentration(IC50)was 0.75 μg·mL-1 by MTT asssy in cell.In the cell cloning assay,the scratch healing area of blank control group,paclitaxel raw material and paclitaxel/natural borneol submicroemulsion were(36.44±3.35)％,(13.59±9.28)％,(8.30±4.09)％,respectively.The results were statistically significant(P＜0.05).In the plate cloning experiment,the cell cloning rates of blank control group,paclitaxel bulk drug group and submicroemulsion group were(37.92±0.729)％,(9.16±1.335)％and(3.36±1.065)％,respectively,the differents were statistically significant(P＜0.05).Conclusion This submicroemulsion has reasonable prescription,feasible process and good stability.Cell experiments showed that the submicronemulision effectively inhibits the proliferation and migration of HCT-116 cells,suggesting its potential as a promising antitumor agent.

Breast cancer is a major public health issue that severely affects women's health. A reasonable perception of disease risk plays an important role in the prevention of breast cancer. This article introduces the definition and development of risk perception, reviews the influencing factors of risk perception in high-risk population for breast cancer, and summarizes the current research status in this field. The aim is to provide a theoretical basis for related research in China and to offer guidance for the development of health behaviors in high-risk population for breast cancer.

Objective:This study aimed to assess the awareness of trainees in physician standardized training towards the consequences of scientific misconduct and identify the main influencing factors, additionally, to provide targeted suggestions.Methods:A questionnaire survey was conducted among 6 200 trainees from 17 National standardized training bases for residencies in Guangxi. The cognitive status of the consequences of scientific misconduct were analyzed and factors affecting trainees' cognition were examined in terms of grade, education level, research experience, publication experience, research integrity training experience, and research integrity knowledge level.Results:The findings indicated that the awareness of trainees towards the consequences of scientific misconduct requires improvement. Notably, trainees from the 2020 and 2021 grade cohorts, with a master′s degree or above, having led research projects, having participated in research integrity training, and with a high level of research integrity knowledge scored higher on the cognitive assessment of the impact of research misconduct.Conclusions:Training bases should prioritize the education of research integrity among trainees, enhance their identification with scientific research integrity, raise their awareness of the seriousness of the consequences of scientific misconduct, and uphold the belief of adhering to the bottom line of academic ethics.

Objective:To evaluate the healthcare accessibility and quality of diagnosis and treatment services of Internet hospitals in China.Methods:One hundred and eighty Internet hospitals in 60 cities were seleted based on the sampling of development levels in the eastern, central and western regions of China. From April to May 2023, standardized patients methodology was applied to evaluate the accessibility(including the number of Internet hospitals, functional settings, online doctor status, the doctor′s attending rate and consultation fees) and diagnosis and treatment service quality(including the diagnosis and treatment services quality, response speed and patient′s evaluation) of Internet hospitals.Results:The average opening rate of Internet hospitals in China was 52.9% (560/1 058), the average online rate of doctors was 64.2% (1 099/1 713), the average doctor′s attending rate was 33.6% (112/333), the average consultation fee was 4.85 yuan, the average score of consultation was 1.92 out of 9, the average score of diagnosis and treatment was 1.12 out of 4, the average score of the response speed was 1.70 out of 3, and patient satisfaction was 2.73 out of 3.Conclusions:The Internet hospital accessibility in China is unevenly developed, and the overall quality of diagnosis and treatment is low. It is recommended to accurately position and optimize the function of Internet hospital, establish the incentive mechanism for online consultation doctors, construct and improve the regulatory system of Internet hospital diagnosis and treatment, so as to improve the accessibility and quality of diagnosis and treatment of Internet hospitals.

Objective To investigate the effectiveness and safety of argatroban combined with antiplatelet therapy in patients with acute mild-to-moderate atherosclerotic cerebral infarction within 72 hours after symptom onset. Methods A total of 452 patients with large atherosclerotic cerebral infarction were enrolled and divided into two groups. The combined therapy group (n=286) received argatroban combined with antiplatelet therapy, while the control group (n=166) received antiplatelet therapy alone. The National Institutes of Health Stroke Scale (NIHSS) score, modified Rankin Scale (mRS) score, early neurological deterioration (END), and occurrence of bleeding events were compared between the two groups using a Logistic regression model. Results Statistically significant differences were observed in age, smoking history, time from stroke onset to admission, low-density lipoprotein, and estimated glomerular filtration rate (eGFR) levels between the two groups (P < 0.05). No significant differences were found in infarction location, responsible artery, and atherosclerotic subtype between the combined therapy and control groups (P>0.05). Among patients with atheroscleroticcerebral infarction, the proportion of patients with an mRS score of 0 to 2 at 90 days after combined therapy of argatrobanwas 85.3%, and was 74.5% in the control group (P < 0.05). In patients with an NIHSS score ≥3, the proportion of patients with an mRS score of 0 to 2 at 90 days in the combined therapy group was 19.3%, which was significantly lower than 60.8% in the control group (P < 0.05). For anterior circulation responsible artery occlusion, the proportion of patients with an mRS score of 0 to 2 at 90 days in the combined therapy group was 82.1%, and 67.2% in the control group (P < 0.05). Among atherosclerotic subtypes, the proportion of patients with penetrating artery occlusion and an mRS score of 0 to 2 at 90 days was significantly higher in the combined therapy group compared to the control group (P < 0.05). Conclusion Argatroban combined with antiplatelet therapy can improve neurological outcomes in patients with acute mild-to-moderate atherosclerotic ischemic stroke without increasing the risk of bleeding. The combined therapy offers more pronounced benefits in patients with anterior circulation ischemia and penetrating artery occlusion.

Humans ; COVID-19/complications* ; SARS-CoV-2 ; Lung ; Abdominal Pain/diagnosis*

Humans ; Cytomegalovirus ; Cytomegalovirus Infections ; Antigens, Viral ; Immunity ; Autoimmune Diseases ; CD8-Positive T-Lymphocytes

Objective:To study the effects of vascular endothelial growth factor (VEGF) inhibitor SU5416 on pulmonary vascular remodeling in neonatal rats with hypoxic pulmonary hypertension (HPH).Methods:Thirty-two neonatal rats (age 7~10 d) were randomly assigned into normoxia group, hypoxia group, SU5416+hypoxia group and SU5416+normoxia group according to corresponding treatments. The endpoint was 14 d after treatments. Right ventricular systolic pressure (RVSP) was measured and cardiac and pulmonary tissue were sampled on the day. Right ventricular hypertrophy index (RVHI) was calculated. After HE staining, the morphological changes of pulmonary vessels were observed under light microscope.Media thickness (MT), external diameter(ED), cross-sectional area of tunica media (MA) and total cross-sectional area(TA) of pulmonary arterioles were measured. MT%(MT/ED) and MA%(MA/TA) were calculated as indicators of pulmonary vascular remodeling. The levels of VEGF and α-smooth muscle actin (α-SMA) in pulmonary vessels were examined using immunohistochemistry (IHC) method.Results:RVSP, RVHI, MT% and MA% in hypoxia group and SU5416+hypoxia group were significantly higher than normoxia group and SU5416+normoxia group ( P<0.05). These indicators in SU5416+hypoxia group were also higher than hypoxia group ( P<0.05),and no significant differences existed between SU5416+normoxia group and normoxia group ( P>0.05). The levels of α-SMA and VEGF in pulmonary vessels in SU5416+hypoxia group and hypoxia group were significantly higher than normoxia group and SU5416+normoxia group ( P<0.05), and α-SMA and VEGF in SU5416+hypoxia group higher than hypoxia group ( P<0.05). Conclusions:VEGF inhibitor SU5416 may exacerbate pulmonary hypertension and increase pulmonary vascular remodeling in neonatal HPH rats.

Europe occupies an important position in the world herbal medicine market. The registration of Traditional Chinese Medicine (TCM) in EU is of great significance to the internationalization of TCM. The European Medicines Agency (EMA) has designed a relatively complete management system and regulatory guidelines for the registration and supervision of herbal medicinal products. The promulgation of the DIRECTIVE 2004/24/EC (2004 / 24 / EC) indicates that TCM could enter the EU market through simplified registration. Based on the registration conditions, registration authority and document guideines of Traditional Herbal Medicinal Products (THMPs) in EU, this paper analyzes the application requirements of simple registration of traditional herbal products in EU, and provides suggestions for the simplified registration of TCM in EU according to the registration requirements of medicinal history, quality requirements and application data format.